BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23295052)

  • 1. Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Min YW; Kim J; Kim S; Sung YK; Lee JH; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Liver Int; 2013 Feb; 33(2):197-202. PubMed ID: 23295052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].
    Jeon SH; Park KS; Kim YH; Shin YS; Kang MK; Jang BK; Chung WJ; Cho KB; Hwang JS
    Korean J Gastroenterol; 2007 Sep; 50(3):176-82. PubMed ID: 17885283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.
    Kim JH; Yoon HK; Kim SY; Kim KM; Ko GY; Gwon DI; Sung KB
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1291-8. PubMed ID: 19392861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study.
    Lee HS; Kim JS; Choi IJ; Chung JW; Park JH; Kim CY
    Cancer; 1997 Jun; 79(11):2087-94. PubMed ID: 9179054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Hiraoka A; Horiike N; Yamashita Y; Koizumi Y; Doi H; Yamamoto Y; Ichikawa S; Hasebe A; Yano M; Miyamoto Y; Ninomiya T; Ootani H; Takamura K; Kawasaki H; Otomi Y; Kogame M; Sogabe I; Ishimaru Y; Kashihara K; Miyagawa M; Hirooka M; Hiasa Y; Matsuura B; Michitaka K; Onji M
    Hepatogastroenterology; 2009; 56(89):213-7. PubMed ID: 19453060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting.
    Zhang XB; Wang JH; Yan ZP; Qian S; Liu R
    Cardiovasc Intervent Radiol; 2009 Jan; 32(1):52-61. PubMed ID: 18931871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic factors and model of primary liver cancer treated with transcatheter arterial chemoembolization combined with radiofrequency ablation].
    Li J; Zhu WL; Kang XX; Zheng L; Guo CY; Yu P; Xiao JC
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):787-791. PubMed ID: 29061025
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test.
    Huang YS; Chiang JH; Wu JC; Chang FY; Lee SD
    Am J Gastroenterol; 2002 May; 97(5):1223-7. PubMed ID: 12014732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk.
    Kothary N; Weintraub JL; Susman J; Rundback JH
    J Vasc Interv Radiol; 2007 Dec; 18(12):1517-26; quiz 1527. PubMed ID: 18057286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.
    Boulin M; Adam H; Guiu B; Aho LS; Cercueil JP; Di Martino C; Fagnoni P; Minello A; Jouve JL; Hillon P; Bedenne L; Lepage C
    Dig Liver Dis; 2014 Apr; 46(4):358-62. PubMed ID: 24462550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
    Hsieh MY; Lin ZY; Chuang WL
    Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization.
    Kim JH; Sinn DH; Lee JH; Hyun D; Cho SK; Shin SW; Chang Y; Kim YJ; Yoon JH; Kang W; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Choi MS
    Dig Dis Sci; 2018 Apr; 63(4):1062-1071. PubMed ID: 29442276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.
    Hsu CY; Huang YH; Su CW; Lin HC; Chiang JH; Lee PC; Lee FY; Huo TI; Lee SD
    Liver Int; 2010 Jan; 30(1):77-84. PubMed ID: 19818004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined transcatheter arterial chemoembolization and beta-ultrasound guided portal vein embolization in the treatment of hepatocellular carcinoma.
    Mao G; Yu Z; Zhang Y; Cheng J
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):391-3. PubMed ID: 12408773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparison of patients with hepatocellular carcinoma between a short-term (less than 6 months) survival group and a long-term (over 24 months) survival group after treatment with transcatheter arterial chemoembolization].
    Kang IK; Kim SW; Hahn SH; Cho SC; Gham CW; Lee DH
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):189-200. PubMed ID: 12499805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma.
    Sasaki A; Iwashita Y; Shibata K; Ohta M; Kitano S; Mori M
    Eur J Surg Oncol; 2006 Sep; 32(7):773-9. PubMed ID: 16797156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors].
    Zhao M; Wang JP; Li W; Huang ZL; Zhang FJ; Fan WJ; Zhang L; Li XS; Pan CC; Wu PH
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(17):1167-72. PubMed ID: 21756768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.